Viloxazine - Revision history

MDElliottMD: Tier 1 taxonomy consolidation: removed redundant Category:Norepinephrine Reuptake Inhibitors (canonical already present)

2026-05-21T17:02:02Z

Tier 1 taxonomy consolidation: removed redundant Category:Norepinephrine Reuptake Inhibitors (canonical already present)

← Older revision		Revision as of 17:02, 21 May 2026
Line 25:		Line 25:
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Non-stimulant ADHD Medicines]]		[[Category:Non-stimulant ADHD Medicines]]
	~~[[Category:Norepinephrine Reuptake Inhibitors]]~~

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:12Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 2:		Line 2:
	\| brand = Qelbree		\| brand = Qelbree
	\| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent		\| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent
	\| mechanism = Selective NET inhibitor (no significant DAT activity — distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine.		\| mechanism = Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine.
	\| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)		\| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)
	\| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.		\| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.
Line 13:		Line 13:
	\| bioavailability = Adequate oral bioavailability with extended-release formulation		\| bioavailability = Adequate oral bioavailability with extended-release formulation
	\| pregnancy = Limited data		\| pregnancy = Limited data
	\| legal = Rx — '''not a controlled substance''' (no DEA scheduling)		\| legal = Rx, '''not a controlled substance''' (no DEA scheduling)
	\| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine — beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy.		\| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine, beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy.

	Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants.		Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants.

MDElliottMD: Remove Category:Psychostimulants tag (second pass after duplicate-tag situation)

2026-05-18T01:01:05Z

Remove Category:Psychostimulants tag (second pass after duplicate-tag situation)

← Older revision		Revision as of 01:01, 18 May 2026
Line 22:		Line 22:
	}}		}}

	~~[[Category:Psychostimulants]]~~
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:Non-stimulant ADHD Medicines]]		[[Category:Non-stimulant ADHD Medicines]]
	[[Category:Norepinephrine Reuptake Inhibitors]]		[[Category:Norepinephrine Reuptake Inhibitors]]

MDElliottMD: Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

2026-05-18T00:48:13Z

Remove Category:Psychostimulants tag (not a psychostimulant — sedative/anxiolytic/anticonvulsant/non-stimulant carryover from Stimulants & Wake-Promoting Agents rename)

← Older revision		Revision as of 00:48, 18 May 2026
Line 22:		Line 22:
	}}		}}

	~~[[Category:Psychostimulants]]~~
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:51:08Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:51, 17 May 2026
Line 22:		Line 22:
	}}		}}

	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:21Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 22:		Line 22:
	}}		}}

	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]

Maintenance script: Expand Viloxazine with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:46Z

Expand Viloxazine with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Viloxazine~~		\| brand = Qelbree
	\| brand = Qelbree		\| classes = Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism, non-stimulant ADHD agent
	~~\| structure =~~		\| mechanism = Selective NET inhibitor (no significant DAT activity — distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine.
	\| classes = NRI, ADHD ~~medicine~~		\| uses = ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult)
	\| mechanism = Selective ~~norepinephrine reuptake~~ inhibitor		\| starting_dose = Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.
	\| uses =		\| preparations = 100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food)
	\| starting_dose =		\| fda_max = 400 mg/d (pediatric); 600 mg/d (adult)
	\| preparations =		\| routes = Oral
	\| fda_max =		\| onset = ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks)
	\| routes =		\| duration = Daily dosing
	\| onset =		\| halflife = ~7 hours
	\| duration =		\| bioavailability = Adequate oral bioavailability with extended-release formulation
	\| halflife =		\| pregnancy = Limited data
	\| bioavailability =		\| legal = Rx — '''not a controlled substance''' (no DEA scheduling)
	\| pregnancy =		\| intro = '''Viloxazine''' (brand name Qelbree) is an extended-release norepinephrine reuptake inhibitor FDA-approved in 2021 for ADHD in children 6 and older, and in 2022 for adults. Originally developed as an antidepressant in Europe in the 1970s (withdrawn for commercial reasons), it was repurposed for ADHD. Like atomoxetine, viloxazine is a non-stimulant alternative that is '''not a controlled substance'''. However, viloxazine has a more complex pharmacology than atomoxetine — beyond pure NET inhibition, it has 5HT1A partial agonism and 5HT2B/5HT7 antagonism, which may underlie faster onset (1-2 weeks vs atomoxetine's 4-6 weeks) and possibly different efficacy.
	\| legal =
	\| intro =		Useful when stimulants are contraindicated, undesirable, or insufficient. Can be combined with stimulants.
	~~\| pharmacokinetics =~~		\| pharmacodynamics= Selective NET inhibition (Ki ~155 nM). 5HT1A partial agonism, 5HT2B antagonism, 5HT2C inverse agonism, 5HT7 antagonism. Minimal DAT activity (key differentiator from stimulants).
	\| pharmacodynamics =		\| effects = Somnolence (most common), decreased appetite, headache, insomnia, fatigue, nausea, irritability. Generally good tolerability. Boxed warning: suicidal ideation in pediatric patients (class warning for SNRIs/antidepressants used in pediatric ADHD).
	~~\| indications =~~		\| interactions = <pharmaInteractions/>
	~~\| dosing~~ =
	\| effects =
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}


	[[Category:Stimulants & Wake-Promoting Agents]]		[[Category:Stimulants & Wake-Promoting Agents]]
Line 36:		Line 26:
	[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]		[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
			[[Category:Non-stimulant ADHD Medicines]]
			[[Category:Norepinephrine Reuptake Inhibitors]]

MDElliottMD: Comprehensive categorization: +Norepinephrine Reuptake Inhibitors (NRIs), Antidepressants

2026-05-15T18:42:06Z

Comprehensive categorization: +Norepinephrine Reuptake Inhibitors (NRIs), Antidepressants

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Stimulants & Wake-Promoting Agents]]		[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
			[[Category:Norepinephrine Reuptake Inhibitors (NRIs)]]
			[[Category:Antidepressants]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:55Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Stimulants & Wake-Promoting Agents]]
	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:13Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =